Venomics AI, a spin-out from the Indian Institute of Science in Bengaluru, raised a $2.7 million pre-seed round co-led by Speciale Invest and South Park Commons, with Operators Studio also participating. The company uses AI to screen animal venom for drug candidates, building what it calls a Venom Atlas - a molecular dataset meant to shortcut the normally slow work of finding usable compounds in venom. It has also been named a top-five finalist for the Indo-Boston Biotech Bridge Award and joined NVIDIA’s Inception programme. On paper, it reads like dozens of other AI-for-drug-discovery raises this year.
The trust problem most AI health startups don’t have an answer for
Any company claiming an AI model can find viable drug candidates faster than traditional methods runs into the same wall immediately: nobody outside the field has a way to verify that claim, and the people who could verify it - pharma researchers, regulators, future licensing partners - are professionally skeptical by default. Most AI drug discovery startups try to solve this with demo videos and partnership logos. Venomics AI solved it before it was a company, because its founder is Kartik Sunagar, an IISc professor whose research on venom evolution and antivenom development predates the startup by years, and its CTO Vinay Prabhu carries a Carnegie Mellon doctorate into the technical half of the pitch.
Why the institution is doing marketing’s job
A founder’s personal brand usually has to be built - LinkedIn posts, conference talks, a podcast circuit, all the machinery InHustler has written about elsewhere. Venomics AI skipped most of that because IISc’s reputation did the work a marketing budget would otherwise have to buy slowly, cheque by cheque, year by year. An investor evaluating an unproven AI claim in a technical field defaults to asking who’s behind it before asking what the product does. When the answer is a named professor with a decade of published, peer-reviewed research in the exact problem the startup claims to solve, the skepticism that usually kills a first pitch meeting never shows up.
The limit of borrowing someone else’s credibility
That advantage has a shelf life. Academic reputation gets a deep-tech startup through the door for a pre-seed round and a handful of early partnerships, but it doesn’t substitute for the startup proving its own track record once it needs commercial licensing deals rather than funding rounds. The real test for Venomics AI isn’t whether Sunagar’s name gets the next meeting - it’s whether the company builds a reputation of its own before investors start asking what the venture, and not the professor, has actually shipped.